Innovodigm Secures ₹5.5 Crore Seed Funding to Revolutionize Vaccine Delivery

Innovodigm, a medical technology startup based in India, has successfully raised ₹5.5 crore in a seed funding round led by the Indian Angel Network (IAN) Group. The funding round saw IAN contributing ₹4.5 crore, while the remaining amount came from PadUp Ventures. The investment aims to bolster Innovodigm’s operations, allowing for process optimization, infrastructure scaling, and team expansion to facilitate third-party preclinical validation and prepare for imminent clinical trials. The announcement was made on June 24, 2025, by the company’s co-founders, Jhimli Manna and Ayan Chatterjee.

Founded in 2020, Innovodigm specializes in the development of micro-array patches (MAP) designed to transform traditional vaccine delivery methods. The innovative patches address several critical issues associated with conventional injectable immunizations, including cold-chain dependency, medical waste, and the risk of needle-stick injuries. Utilizing thermostabilized vaccines, Innovodigm's MAP allows for storage at temperatures of up to 40°C for up to 120 days, significantly reducing the necessity for refrigeration. This feature enhances the accessibility of vaccines in remote and underserved regions, a crucial factor in public health initiatives.

According to Innovodigm CEO Jhimli Manna, “Spinning out from IIT Kharagpur’s Microelectronics and MEMS Lab has been fundamental to our scientific foundation. Our MAP platform reflects India’s ability to lead in affordable, scalable vaccine delivery that serves both national and global public health goals.” The MAP technology has already gained recognition, being selected as one of the Top 2 Technologies at the Nano Electronics Showcase 2025, hosted by the Ministry of Electronics and Information Technology.

The startup recently signed a Material Transfer Agreement (MTA) with a leading Indian vaccine manufacturer, which will facilitate third-party validation of its technology. Clinical trials are slated to begin next year, marking a significant step forward in the company’s mission to adapt its patch for various vaccines, including those for measles, hepatitis, flu, and COVID-19 boosters.

Innovodigm's strategy includes expanding its operations not only across India but also into other low- and middle-income countries. The company aims to establish local manufacturing hubs to ensure that vaccine patches are produced closer to the regions that require them the most. This approach aligns with global efforts to enhance vaccine accessibility and affordability.

In summary, Innovodigm's recent funding round and its innovative MAP technology represent a promising advancement in the medical technology sector, with the potential to significantly improve vaccine delivery systems worldwide. The implications of this technology could lead to a transformative change in public health, particularly in regions that have historically faced challenges related to immunization access and logistics.